Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Investigational Coating Clear all
Terminated Not applicable Interventional Results available

Adjunctive Transcranial Direct Current Stimulation

NCT02665988
View directory record Official record
Conditions
Chronic Pain, Psychiatric Disorders
Interventions
tDCS, Sham tDCS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Not applicable Interventional Results available

Clinical Characterization of an Investigational Soft Silicone Hydrogel Contact Lens

NCT04631796
View directory record Official record
Conditions
Refractive Errors
Interventions
Lehfilcon A contact lenses, Multipurpose disinfection solution
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Orlando, Florida • Bloomington, Illinois • Powell, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of PRP for Treatment of Disc Pain

NCT04064866
View directory record Official record
Conditions
Discogenic Pain
Interventions
High yield pure PRP, Placebo, ProPlaz PPC
Device · Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 23, 2026, 9:19 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

NCT06770933
View directory record Official record
Conditions
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Interventions
VX-01, Placebo
Drug
Lead sponsor
Vantage Biosciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

NCT06673654
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 23, 2026, 9:19 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

NCT06792539
View directory record Official record
Conditions
Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Interventions
Polymotion Hip Resurfacing (PHR) System
Device
Lead sponsor
JointMedica Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

NCT07641738
View directory record Official record
Conditions
Microvascular Disease, Retinal Disease
Interventions
XyCAM CRE Imaging
Device
Lead sponsor
Stuart Terry Eye Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
VYN201 Gel, Vehicle Gel
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of a Monofocal Intraocular Lens

NCT06428955
View directory record Official record
Conditions
Cataract
Interventions
CT LUCIA 621P
Device
Lead sponsor
Carl Zeiss Meditec AG
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Lexington, Kentucky • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Recruiting Early Phase 1 Interventional

ENDOTRACHEAL Tube LIDOCAINE

NCT07709390
View directory record Official record
Conditions
Emergency Coughing
Interventions
5% Lidocaine Ointment, Water-Based Lubricant
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022
View directory record Official record
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 23, 2026, 9:19 AM EDT
Recruiting Not applicable Interventional

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

NCT06910306
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliomas
Interventions
Device :DaRT seeds
Device
Lead sponsor
Alpha Tau Medical LTD.
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 4 Interventional Results available

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Macitentan, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema

NCT02691507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 23, 2026, 9:19 AM EDT
Terminated Not applicable Interventional Results available

Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)

NCT02813577
View directory record Official record
Conditions
Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
Interventions
Lutonix® 035 Drug Coated Balloon PTA Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Indianapolis, Indiana • Davenport, Iowa • Orangeburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 23, 2026, 9:19 AM EDT
Recruiting Phase 4 Interventional

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

NCT06379724
View directory record Official record
Conditions
Burns, Skin Graft Complications
Interventions
Tranexamic acid, Thrombin JMI, skin graft
Drug · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Not applicable Interventional Results available

Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries

NCT01412541
View directory record Official record
Conditions
Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
Interventions
Standard Uncoated Angioplasty Balloon, Moxy Drug Coated Balloon
Procedure · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
42
States / cities
Los Angeles, California • Oceanside, California • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 23, 2026, 9:19 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

NCT03241459
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
Interventions
Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB
Device
Lead sponsor
SurModics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 23, 2026, 9:19 AM EDT